Literature DB >> 22057910

Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.

Robb D Kociol1, Bradley G Hammill, Adrian F Hernandez, Winslow Klaskala, Roger M Mills, Lesley H Curtis, Gregg C Fonarow.   

Abstract

BACKGROUND: Hospitalized medically ill patients are at greater risk for venous thromboembolism (VTE). Although pharmacologic prophylaxis regimens have reduced VTE risk in medically ill patients, associations with early postdischarge adverse clinical outcomes among patients with heart failure are unknown. HYPOTHESIS: We hypothesized that patients receiving pharmacologic VTE prophylaxis during hospitalization for heart failure would have lower rates of postdischarge adverse clinical outcomes than patients not receiving prophylaxis.
METHODS: Using data from the Acute Decompensated Heart Failure (ADHERE) registry linked to Medicare claims, we estimated 30-day postdischarge outcome rates for patients who received in-hospital subcutaneous heparin compared with patients who did not receive in-hospital VTE prophylaxis. We excluded patients who received warfarin or intravenous heparin. Outcomes included mortality, thromboembolic events, major adverse cardiovascular events, and all-cause readmission. We used propensity-score methods to estimate associations between VTE prophylaxis and each outcome. In a secondary analysis, we compared outcomes of patients receiving pharmacologic prophylaxis with unfractionated heparin (UFH) vs low-molecular-weight heparin (LMWH).
RESULTS: Of 36 799 eligible patients in 265 hospitals, 12 169 (33%) received pharmacologic VTE prophylaxis during the hospitalization. In unadjusted analysis and after weighting by the inverse probability of treatment, VTE prophylaxis was not associated with 30-day postdischarge mortality, thromboembolic events, major adverse cardiovascular events, or all-cause readmission. There were no differences in outcomes between patients receiving UFH and those receiving LMWH.
CONCLUSIONS: Pharmacologic VTE prophylaxis is provided to one-third of older patients hospitalized with heart failure. Treatment with LMWH or UFH did not have a statistically significant association with 30-day postdischarge outcomes.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057910      PMCID: PMC6652431          DOI: 10.1002/clc.20986

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Successful Resident Engagement in Quality Improvement: The Detroit Medical Center Story.

Authors:  Syed Ahmed Hussain; Camelia Arsene; Corinne Hamstra; Tess H Woehrlen; Wilhelmine Wiese-Rometsch; Suzanne R White
Journal:  J Grad Med Educ       Date:  2016-05

2.  Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA.

Authors:  Alpesh Amin; W Richey Neuman; Melissa Lingohr-Smith; Brandy Menges; Jay Lin
Journal:  Drugs Context       Date:  2019-01-21

3.  Current practice and effects of intravenous anticoagulant therapy in hospitalized acute heart failure patients with sinus rhythm.

Authors:  Hiroki Nakano; Yasuhiro Hamatani; Toshiyuki Nagai; Michikazu Nakai; Kunihiro Nishimura; Yoko Sumita; Hisao Ogawa; Toshihisa Anzai
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

4.  Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.

Authors:  S Phani Veeranki; Zhimin Xiao; Andrée Levorsen; Meenal Sinha; Bimal R Shah
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-14       Impact factor: 3.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.